Gateway Theory: Does Cannabis Use Lead to Harder Drugs?

In the early 1980s the concept of cannabis being a “gateway” to the use of “harder” drugs was introduced as a justification for prohibition of cannabis and prosecution of users. Unfortunately, this Gateway Theory had not been scientifically investigated at the time it was introduced, and despite subsequent science that has demonstrated this theory to be incorrect, lawmakers and politicians continue to refer to it when justifying their positions. This article will summarize the actual data that has been accumulated over the ensuing 40 plus years since this theory made its debut.

Cannabinoid-Based Therapies for the Treatment of Multiple Sclerosis

Many diseases affect the central nervous system, but Multiple Sclerosis (MS) is the most prevalent. MS affects 2.8 million people worldwide, primarily affecting more women than men (Karabudak et al., 2015). Multiple sclerosis is a chronic, immune-mediated disease that targets the central nervous system and is characterized by the immune system attacking the myelin sheath.

Observational Data Are Valuable, but RCTs Remain Essential

The clinical use of cannabinoid-based therapies has accelerated dramatically over the past decade, supported by extensive observational research, patient registries, and clinical anecdotes.

Delta-7 THC, Delta-8 THC, Delta-9 THC, Delta-10 THC, HHC, & more

Hemp is seriously complicating the cannabis world.  This is making it harder to treat patients and to safeguard the public health.  There is a range of historical reasons that have led us to this quagmire but regardless of the history and rationale, we have to understand the current situation and how that affects our patients.  

Recommendation to Change the Term Adult-Use to Non-medical Use

Association of Cannabinoid Specialists (ACS) proposes that the term “adult-use” be changed to “non-medical use” in all communication, laws, and regulation.  The term “adult-use” is inaccurate, stigmatizing, and harmful to the community whereas “non-medical use” is accurate, supportive, and will decrease confusion among consumers.

ACS Calls on FDA to do More Than Send Letters to Cannabis Companies

Recently the FDA has sent a warning letter to a California company for marketing an injectable CBD product.  As reported via a variety of outlets, FDA cited multiple legal infractions and gave the company 15 days to comply with all laws and regulations.  Further legal action, of any unspecified nature, was implied in the letter if compliance was not ensured by the due date.  

Understanding Cannabis Testing: Ensuring Safety and Quality

The cannabis industry is growing at an unprecedented pace, driven by the legalization wave across the globe. However, as the market expands, so too does the need for robust testing to ensure the safety, quality, and consistency of products. 

Supporting Your Own Endocannabinoid System Beyond Cannabis

While cannabis has garnered significant attention for its unique ability to interact with the human Endocannabinoid System, maintaining the health and balance of this vital system can be achieved or supported in ways that are not simply consuming cannabis. A holistic approach that encompasses diet, lifestyle, and therapeutic practices can produce the best results.

Clinical Endocannabinoid Deficiency: An Emerging Paradigm

The concept of Clinical Endocannabinoid Deficiency (CED) is a hypothesis that suggests an underactive endocannabinoid system (ECS) may contribute to the pathogenesis of certain chronic conditions.

5 Tips for Evaluating that New Research Study on Cannabis

You’re scrolling through your news feed and you come across an announcement about a new study that claims cannabis use causes heart disease.

Should you believe it? Is it trustworthy? How can you tell?

Cannabis and Driving: Navigating the Risks and Realities

As the legalization of cannabis continues to spread across the United States, a critical concern that has emerged is the increase in driving under the influence of cannabis. This trend poses significant challenges to road safety and public health. Understanding the implications of cannabis-impaired driving is essential for policymakers, patients, and the general public.

Why Physicians & Clinicians Should Seek Education about Cannabis

If you’re like most physicians, you are likely ignoring most of the hubbub about cannabis that is in the news these days.  Your patients certainly aren’t.   

Happy Holidays from the Association of Cannabinoid Specialists!

The Association of Cannabinoid Specialists wishes you a warm, peaceful, and merry holiday season. Let's reflect on some of the accomplishments we've made together in 2024.

Delta-8 THC versus Delta-9 THC: What is the Difference?

Delta-8 THC and delta-9 THC are both types of tetrahydrocannabinol (THC), the main compounds found in the cannabis plant. They have similar chemical structures but are regulated differently and have different safety profiles. This discussion focuses on these two aspects to better understand their potential effects and risks on our patients.

5 Things Medical Students Should Know About Medical Cannabis

With 10+ years counseling patients on the use of medical cannabis, here are 5 tips I wish I had known earlier in my career.

Member Spotlight: Bria N. Brumfield, ACS Student Member

Q: Tell us a little bit about yourself.

A: My name is Bria N. Brumfield. I am 23 years old with a Bachelors of science in Health Science from Spelman College. I am currently receiving my Master of Science in Biotechnology & Medical Cannabis Therapy while being a full-time Clinical Research Coordinator at Lurie Children’s Hospital in Chicago, IL.

ACS Presents: Introduction to Cannabinoid Medicine CME Course

Our patients are likely struggling with cannabis more than you realize. While medical and recreational legalization have been moving quickly and seem like “it’s all fun and games”, the reality is that our patients, whether using medically or recreationally, need our intervention and guidance more than ever.

Psychedelics: A Clinical Perspective Symposium Synopsis

On Tuesday, October 22, 2024, the Association of Cannabinoid Specialists welcomed Eugene Vortsman, DO to present on Psychedelic Medicine: A Clinical Perspective.

Medical Use of Cannabinoids as Applied to Special Groups

Association of Cannabinoid Specialists (ACS) wishes to reiterate that, to the extent that medical use of cannabis or cannabinoid medicines is available to the general public in any jurisdiction and supported by human-based scientific evidence, all patients must have access to such cannabinoid treatment when offered under the guidance of a duly-authorized medical prescriber.  

Position on Medical Use of Cannabinoids for Prisoners and Parolees

A Response to Pending Hearing in the Case of State of West Virginia vs. Schober

The Endocannabinoid System, Colitis, and the Use of Cannabis for IBD

Preclinical data supports the use of cannabinoids for gastrointestinal inflammation, but does this translate into patient outcomes?

Questions Patients Ask (That Doctors Should Know How to Answer)

When considering medical cannabis, patients often have numerous questions for their physicians. These questions typically revolve around safety, efficacy, legal issues, and personal concerns. Here are some of the most common questions patients are likely to ask their physicians about medical cannabis:

ACS Presents: A Policy Panel on Rescheduling and Medical Cannabis

On September 24, 2024, the Association of Cannabinoid Specialists (www.cannaspecialists.com) hosted a paneled event surrounding the topic of policy and rescheduling, and what it means for patients and clinicians.

ACS Member Spotlight: Alicia Schaal, BSN, RN, PHN, Student

Q: Tell us a little bit about yourself.

A: My name is Alicia Schaal, I am a health care professional, and I'm the owner and CEO of Midwest Cannabis Professionals, LLC, a medical cannabis consulting company based in Minneapolis, MN.

Colitis and the Endocannabinoid System: Unveiling Preclinical Insights

With the incidence of colitis on the rise, is cannabis the cure we’ve been waiting for?

Opportunities for Pharmacists in the Medical Cannabis Industry

While cannabis as medicine is not new, the healthcare provider’s venture into the cannabis industry may be a new journey for many. In state medical marijuana programs doctors are the people who “recommend” cannabis (presently there is no actual prescription for cannabis).

Cannabis Use Disorder and the Importance of Physician Guidance

In recent years, cannabis, also known as marijuana, has become more prevalent and accepted in many societies around the world. With the legalization of cannabis for medical and recreational use in several states and countries, its consumption has significantly increased.

Overview of Minor Cannabinoids, Terpenes, and Potential Uses

On July 23, 2024, the Association of Cannabinoid Specialists was proud to invite ACS President and Founder Jordan Tishler, MD back to the podium as he presented on an Overview of Minor Cannabinoids, Terpenes, and Potential Uses.

ACS Comment to DEA Rescheduling Rule

The Association of Cannabinoid Specialists (ACS) is an international non-profit organization of physicians and other health professionals specializing in using cannabis or cannabinoids, as appropriate, for the care and treatment of patients suffering from a range of debilitating conditions such as cancer, Crohn’s disease, AIDS, multiple sclerosis, Parkinson’s disease, epilepsy, autism, and post-traumatic stress disorder, and patients with terminal illnesses.

Cannabis and Anxiety: Navigating the Complex Relationship for Therapeutic Use

Over the years, I have had the privilege of caring for a multitude of patients turning to cannabis as a therapeutic option for anxiety, spanning from general anxiety disorder and situational anxiety to its role in managing PTSD and accompanying depression.